Top Markets
#1 Nesa Nesa +775.61%
#2 Cortex Cortex +68.81%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.79%
#4 QuantixAI QuantixAI +32.58%
#5 EXOD EXOD +22.78%
#6 Pons Pons +22.47%
#7 Venom Venom +11.06%
#8 Renzo Restaked LST Renzo Restaked LST +10.31%
#9 Movement Movement +10.08%
#10 Fartcoin Fartcoin +9.75%
Coin of the day
Nesa Nesa
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Hangzhou Tigermed Consulting Co., Ltd Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd

300347
Classifica tra le azioni #3375
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Prezzo delle azioni
$7.46
Capitalizzazione di mercato
$5.51B
Variazione (1 giorno)
-1.49%
Variazione (1 anno)
-18.39%
Paese
CN
Scambia Hangzhou Tigermed Consulting Co., Ltd (300347)

Categoria

Healthcare
Rapporto P/E per Hangzhou Tigermed Consulting Co., Ltd (300347)
Rapporto P/E al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Hangzhou Tigermed Consulting Co., Ltd, il rapporto P/E attuale (TTM) è 0. Alla fine del 2026, il rapporto P/E era 0.
Storico del rapporto P/E per Hangzhou Tigermed Consulting Co., Ltd da 2026 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
Non abbastanza dati per le date fornite.
Rapporto P/E per aziende simili o concorrenti
Azienda P/E Ratio Differenza del P/E Ratio Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.